APLS insider buying and SEC filings, explained
Apellis Pharmaceuticals, Inc. · CIK 1492422
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$2.6M
Planned sales (10b5-1)
$223K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Feb 11, 2026 | Sale | Mark Jeffrey DeLong (Chief Business & Strat Officer) sold 368 shares at $22.15 ($8K). Holdings down <1% to 114,591 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Jan 22, 2026 | Sale | Caroline Baumal (Chief Medical Officer) sold 2,797 shares at $21.77 ($61K). Holdings down 3% to 86,527 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | James George Chopas (VP/Chief Accounting Officer) sold 2,064 shares at $21.77 ($45K). Holdings down 4% to 49,805 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | Mark Jeffrey DeLong (Chief Business & Strat Officer) sold 3,371 shares at $21.77 ($73K). Holdings down 4% to 78,353 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | Pascal Deschatelets (Chief Scientific Officer) sold 5,928 shares at $21.77 ($129K). Holdings down 1% to 1,151,382 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | Cedric Francois (CEO and Director) sold 27,192 shares at $21.77 ($592K). Holdings down 9% to 286,045 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | Nur Nicholson (Chief Technical Officer) sold 7,725 shares at $21.77 ($168K). Holdings down 10% to 71,118 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | Timothy Eugene Sullivan (CFO) sold 10,287 shares at $21.77 ($224K). Holdings down 10% to 93,901 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 22, 2026 | Sale | David O. Watson (General Counsel) sold 7,832 shares at $21.77 ($171K). Holdings down 8% to 88,531 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 23, 2026 |
| Jan 20, 2026 | Sale | Caroline Baumal (Chief Medical Officer) sold 1,882 shares at $19.79 ($37K). Holdings down 2% to 89,324 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 20, 2026 | Sale | James George Chopas (VP/Chief Accounting Officer) sold 726 shares at $19.79 ($14K). Holdings down 1% to 51,869 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 20, 2026 | Sale | Mark Jeffrey DeLong (Chief Business & Strat Officer) sold 1,334 shares at $19.79 ($26K). Holdings down 2% to 81,724 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 20, 2026 | Sale | Pascal Deschatelets (Chief Scientific Officer) sold 909 shares at $19.79 ($18K). Holdings down <1% to 1,157,310 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 20, 2026 | Sale | Cedric Francois (CEO and Director) sold 8,182 shares at $19.79 ($162K). Holdings down 3% to 313,237 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 20, 2026 | Sale | Nur Nicholson (Chief Technical Officer) sold 2,203 shares at $19.79 ($44K). Holdings down 3% to 78,843 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 20, 2026 | Sale | Timothy Eugene Sullivan (CFO) sold 2,892 shares at $19.79 ($57K). Holdings down 3% to 104,188 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 20, 2026 | Sale | David O. Watson (General Counsel) sold 2,475 shares at $19.79 ($49K). Holdings down 3% to 96,363 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 21, 2026 |
| Jan 13, 2026 | Sale | James George Chopas (VP/Chief Accounting Officer) sold 873 shares at $22.19 ($19K). Holdings down 2% to 52,595 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 13, 2026 | Sale | Mark Jeffrey DeLong (Chief Business & Strat Officer) sold 1,780 shares at $22.19 ($39K). Holdings down 2% to 83,058 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 13, 2026 | Sale | Pascal Deschatelets (Chief Scientific Officer) sold 2,277 shares at $22.19 ($51K). Holdings down <1% to 1,158,219 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 13, 2026 | Sale | Cedric Francois (CEO and Director) sold 10,186 shares at $22.19 ($226K). Holdings down 3% to 321,419 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 13, 2026 | Sale | Nur Nicholson (Chief Technical Officer) sold 2,618 shares at $22.19 ($58K). Holdings down 3% to 81,046 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 13, 2026 | Sale | Timothy Eugene Sullivan (CFO) sold 3,856 shares at $22.19 ($86K). Holdings down 3% to 107,080 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 13, 2026 | Sale | David O. Watson (General Counsel) sold 5,780 shares at $22.19 ($128K). Holdings down 6% to 98,838 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 15, 2026 |
| Jan 5, 2026 | Sale | Caroline Baumal (Chief Medical Officer) sold 3,020 shares at $25.53 ($77K). Holdings down 3% to 91,206 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 6, 2026 |
| Dec 16, 2025 | Planned (10b5-1) | David O. Watson (General Counsel) sold 5,000 shares at $24.49 ($122K), marked as a 10b5-1 plan trade. Holdings down 5% to 103,730 shares. | SEC filing Filed Dec 18, 2025 |
| Nov 17, 2025 | Planned (10b5-1) | David O. Watson (General Counsel) sold 5,000 shares at $20.06 ($100K), marked as a 10b5-1 plan trade. Holdings down 4% to 108,730 shares. | SEC filing Filed Nov 18, 2025 |
41 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow APLS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.